tailieunhanh - A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

The aim of this study was to determine whether checkpoint kinase 1 inihibitor (CHK1), LY2603618, and gemcitabine prolong overall survival (OS) compared to gemcitabine alone in patients with unresectable pancreatic cancer. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN